Back
17
Day Range
$19.92
$20.74
52-Week Range
$11.84
$24.99
Volume
902,623
50D / 200D Avg
$20.72
/
$18.21
Prev Close
$19.70
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 10.7 | 0.4 |
| P/B | 2.0 | 2.9 |
| ROE % | 20.3 | 3.8 |
| Net Margin % | 8.6 | 3.9 |
| Rev Growth 5Y % | 0.0 | 10.0 |
| D/E | 0.8 | 0.2 |
Key Takeaways
Revenue grew 0.03% annually over 5 years — modest growth
ROE of 20.28% indicates high profitability
Generating 252.63M in free cash flow
P/E of 10.70 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.95%
Cash machine — converts 152.75% of earnings into free cash flow
Growth
Revenue Growth (5Y)
0.03%
Revenue (1Y)-4.92%
Earnings (1Y)N/A
FCF Growth (3Y)55.86%
Quality
Return on Equity
20.28%
ROIC11.36%
Net Margin8.64%
Op. Margin12.07%
Safety
Debt / Equity
0.76
Current Ratio1.66
Interest Coverage6.43
Valuation
P/E Ratio
10.70
P/B Ratio2.04
EV/EBITDA8.89
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -4.92% | Revenue Growth (3Y) | -2.05% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 0.03% | Earnings Growth (5Y) | 6.01% |
| Profitability | |||
| Revenue (TTM) | 1.91B | Net Income (TTM) | 165.39M |
| ROE | 20.28% | ROA | 7.36% |
| Gross Margin | 24.66% | Operating Margin | 12.07% |
| Net Margin | 8.64% | Free Cash Flow (TTM) | 252.63M |
| ROIC | 11.36% | FCF Growth (3Y) | 55.86% |
| Safety | |||
| Debt / Equity | 0.76 | Current Ratio | 1.66 |
| Interest Coverage | 6.43 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 10.70 | P/B Ratio | 2.04 |
| P/S Ratio | 0.92 | PEG Ratio | -0.04 |
| EV/EBITDA | 8.89 | Dividend Yield | 0.00% |
| Market Cap | 1.77B | Enterprise Value | 2.05B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.91B | 2.01B | 1.99B | 1.97B | 1.91B |
| Net Income | 165.39M | -99.07M | -60.41M | 66.34M | 130.96M |
| EPS (Diluted) | 1.94 | -1.19 | -0.73 | 0.79 | 1.52 |
| Gross Profit | 471.88M | 454.34M | 421.57M | 467.03M | 513.24M |
| Operating Income | 231.09M | -68.71M | 7.32M | 172.69M | 202.92M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.25B | 2.15B | 2.22B | 2.35B | 2.72B |
| Total Liabilities | 1.38B | 1.39B | 1.37B | 1.46B | 1.83B |
| Shareholders' Equity | 865.85M | 764.94M | 849.06M | 891.63M | 896.49M |
| Total Debt | 660.30M | 662.31M | 701.65M | 717.08M | 1.07B |
| Cash & Equivalents | 375.24M | 229.94M | 73.26M | 9.82M | 387.39M |
| Current Assets | 763.51M | 639.61M | 483.45M | 427.99M | 840.56M |
| Current Liabilities | 458.91M | 434.11M | 388.95M | 426.98M | 427.37M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#449 of 658
Recent Activity
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026